Valeritas Holdings Inc (NASDAQ:VLRX) traded up 25% during mid-day trading on Wednesday . The stock traded as high as $0.51 and last traded at $0.41, 3,320,112 shares traded hands during mid-day trading. An increase of 392% from the average session volume of 674,399 shares. The stock had previously closed at $0.33.
Several analysts recently issued reports on the company. ValuEngine cut Valeritas from a “buy” rating to a “hold” rating in a research note on Saturday, December 21st. BTIG Research cut Valeritas from a “buy” rating to a “neutral” rating in a research note on Monday, December 23rd. Zacks Investment Research raised Valeritas from a “sell” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Oppenheimer cut Valeritas from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd.
The company has a debt-to-equity ratio of 1.74, a current ratio of 2.08 and a quick ratio of 1.63. The company has a market capitalization of $3.04 million, a P/E ratio of -0.03 and a beta of 1.72. The company has a 50 day moving average of $0.63 and a 200-day moving average of $1.43.
In related news, major shareholder Armistice Capital, Llc sold 1,060,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $0.75, for a total value of $795,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.02% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in Valeritas in the second quarter worth about $68,000. Millennium Management LLC purchased a new stake in Valeritas in the third quarter worth about $77,000. Finally, Wedbush Securities Inc. lifted its holdings in Valeritas by 449.1% in the fourth quarter. Wedbush Securities Inc. now owns 90,000 shares of the company’s stock worth $52,000 after buying an additional 73,609 shares during the period. Institutional investors and hedge funds own 18.18% of the company’s stock.
About Valeritas (NASDAQ:VLRX)
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.